Reporte zur Charge USAA225

Symptomtext

a pregnant employee that was given FLUBLOK. with no reported adverse event; Initial information received on 05-Oct-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 26 years old female patient who was exposed to vaccine INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK] in context of a pregnant employee that was given flublok. with no reported adverse event. Data regarding this pregnancy were received prospectively, i.e. before pregnancy outcome was known. The reported a pregnant employee that was given FLUBLOK. with no reported adverse event occurred at 21 weeks of pregnancy and the patient was exposed to INFLUENZA QUADRIVALENT RECOMBINANT VACCINE at 21 weeks of pregnancy, during second pregnancy trimester for INFLUENZA QUADRIVALENT RECOMBINANT VACCINE. The date of last menstrual period was reported as 13-May-2022. The estimated due date is 17-Feb-2023. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications: none. On 30-Sep-2022, the patient received a dose of 0.5 ml of suspect INFLUENZA QUADRIVALENT RECOMBINANT VACCINE (formulation, strength: unknown) lot USAA225 via intramuscular route in the left deltoid as Immunization. On 30-SEP-2022 the pregnant employee was given flublok with no reported adverse event (exposure during pregnancy) same day following the administration of INFLUENZA QUADRIVALENT RECOMBINANT VACCINE. Action taken was not applicable. It was not reported if the patient received a corrective treatment for the event (a pregnant employee that was given FLUBLOK. with no reported adverse event). At time of reporting, the outcome was Unknown for the event